Abahssain Halima, Afchain Pauline, Melas Nawfal, Ismaili Nabil, Rahali Rabia, Rabti Hind M, Errihani Hassan
Institut national d'oncologie, service d'oncologie médicale, 10100 Rabat, Maroc.
Presse Med. 2010 Dec;39(12):1238-45. doi: 10.1016/j.lpm.2010.09.002. Epub 2010 Nov 11.
Gallbladder cancer is an aggressive tumor. Its incidence varies according to geography. Surgery is the standard treatment for localized stage but there is no standard treatment in metastatic or locally advanced disease. Because of the rarity of bile tract cancer (BTC) and gallblader carcinoma (GBC), most studies have grouped all BTC and GBC together, and there are very few GBC-specific studies. In addition, there is a paucity of randomized controlled studies in this disease with small numbers of patients and inclusion bias. One randomized trial ABC-02 was well conducted and showed a survival benefit in favor of gemcitabine (GEM)+cisplatin (CDDP), which can be regarded as the standard in locally advanced BTC. Adjuvant therapy after surgical resection is not validated. Understanding the molecular mechanisms of carcinogenesis of GBC has opened the way for the use of targeted therapies. This new treatment would improve survival and quality of life of our patients.
胆囊癌是一种侵袭性肿瘤。其发病率因地域而异。手术是局限性阶段的标准治疗方法，但对于转移性或局部晚期疾病尚无标准治疗方案。由于胆管癌（BTC）和胆囊癌（GBC）较为罕见，大多数研究将所有BTC和GBC归为一类，而针对GBC的特异性研究很少。此外，该疾病的随机对照研究较少，患者数量少且存在纳入偏倚。一项随机试验ABC - 02进行得很好，显示吉西他滨（GEM）+顺铂（CDDP）有生存获益，可被视为局部晚期BTC的标准治疗方案。手术切除后的辅助治疗尚未得到验证。了解GBC的致癌分子机制为靶向治疗的应用开辟了道路。这种新的治疗方法将改善我们患者的生存率和生活质量。
